Survival of antigen-specific antibody following administration of intravenous immunoglobulin in patients with primary immunodeficiency diseases.
To measure the survival of IgG, IgG subclasses and antigen-specific antibody in immune-deficient patients, we infused 4 patients with X-linked agammaglobulinemia (XLA) and 6 patients with common variable immune deficiency (CVID) with modified immunoglobulin at a dose of 400 mg/kg per month until steady state was reached. Following the 8th monthly infusion, serial samples were obtained and analyzed for serum concentration of IgG, IgG subclasses and for specific antibody activities against a battery of antigens. Half-lives for IgG and IgG subclasses were between 30 and 40 days except for IgG3 which appeared to consist of two populations of molecules, one showing a rapid decay, the other disappearing at a rate suggesting a half life of 22-24 days. Antigen-specific antibodies, including antibodies to HBsAg, cytomegalovirus, pneumococcal polysaccharides and streptococcal group A carbohydrate were similar to that for total IgG. These studies demonstrate that protective antibody titers to infective agents can be maintained for several weeks following high-dose intravenous immunoglobulin infusion.
Fischer
S H
SH
Department of Pediatrics, University of Washington School of Medicine, Seattle.
Ochs
H D
HD
Wedgwood
R J
RJ
Skvaril
F
F
Morell
A
A
Hill
H R
HR
Schiffmann
G
G
Corey
L
L
D000293:Adolescent; D000328:Adult; D000361:Agammaglobulinemia / Q000276:immunology / Q000628:therapy*; D000906:Antibodies / Q000032:analysis; D000917:Antibody Formation; D002648:Child; D004406:Dysgammaglobulinemia / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D017099:IgG Deficiency; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000032:analysis / Q000145:classification*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D000906:Antibodies; D007074:Immunoglobulin G